Results 21 to 30 of about 106,022 (294)

Mechanisms and possible hepatoprotective effects of glucagon-like peptide-1 receptor agonists and other incretin receptor agonists in non-alcoholic fatty liver disease.

The Lancet Gastroenterology and Hepatology, 2023
Glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) are incretins that stimulate insulin secretion from pancreatic β cells in response to food ingestion.
G. Targher, A. Mantovani, C. Byrne
semanticscholar   +1 more source

Discontinuing glucagon‐like peptide‐1 receptor agonists and body habitus: A systematic review and meta‐analysis

Obesity Reviews
Research on Glucagon‐like peptide 1 receptor agonist (GLP‐1RA) has mainly focused on the efficacy of weight loss and not the long‐term efficacy of weight loss maintenance.
Sara Berg, Hannah Stickle, Suzanne J. Rose, Eric C. Nemec   +3 more
semanticscholar   +1 more source

National Trends in Use of Sodium‐Glucose Cotransporter‐2 Inhibitors and Glucagon‐like Peptide‐1 Receptor Agonists by Cardiologists and Other Specialties, 2015 to 2020

Journal of the American Heart Association : Cardiovascular and Cerebrovascular Disease, 2022
Background Sodium‐glucose cotransporter‐2 inhibitors (SGLT2is) and glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) mitigate cardiovascular risk in individuals with type 2 diabetes, but most eligible patients do not receive them.
Rishav Adhikari, K. Jha, MS ZeinaDardari, Mph James Heyward, R. Blumenthal, R. Eckel, G. Alexander, M. J. Blaha, J. Hopkins   +8 more
semanticscholar   +1 more source

Neuroprotective effects of lixisenatide against propagation of α-synuclein pathology in Parkinson’s disease

Neural Regeneration Research
Glucagon-like peptide-1 receptor agonists, originally developed for the treatment of type 2 diabetes mellitus, have been suggested as a potential disease-modifying treatment for Parkinson’s disease.
Shangqi Sun, Liqin Huang, Gege Jiang, Guanfeng Xie, Xiaoyi Li, Xiufeng Wang, Hongxiu Guo, Cailin Wang, Siyi Zheng, Gang Li, Jing Xiong   +10 more
doaj   +1 more source

Elective peri‐operative management of adults taking glucagon‐like peptide‐1 receptor agonists, glucose‐dependent insulinotropic peptide agonists and sodium‐glucose cotransporter‐2 inhibitors: a multidisciplinary consensus statement

Anaesthesia
Glucagon‐like peptide‐1 receptor agonists, dual glucose‐dependent insulinotropic peptide receptor agonists and sodium‐glucose cotransporter‐2 inhibitors are used increasingly in patients receiving peri‐operative care.
K. El-Boghdadly, J. Dhesi, Philippa Fabb, N. Levy, D. Lobo, A. McKechnie, Omar G Mustafa, P. Newland-Jones, Anil Patel, D. Pournaras, K. Clare, K. Dhatariya   +11 more
semanticscholar   +1 more source

Sex Differences in Response to Treatment with Glucagon-like Peptide 1 Receptor Agonists: Opportunities for a Tailored Approach to Diabetes and Obesity Care

Journal of Personalized Medicine, 2022
The available data suggest differences in the course of type 2 diabetes mellitus (T2DM) between men and women, influenced by the distinguishing features of the sex.
Elpiniki Rentzeperi, Stavroula Pegiou, T. Koufakis, M. Grammatiki, K. Kotsa   +4 more
semanticscholar   +1 more source

Risk of Non‐Arteritic Anterior Ischemic Optic Neuropathy in Idiopathic Intracranial Hypertension Patients Treated with GLP‐1 Receptor Agonists

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Introduction Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) have demonstrated significant weight‐reducing effects and may offer benefits in idiopathic intracranial hypertension (IIH); however, recent concerns about the risk of non‐arteritic anterior ischemic optic neuropathy (NAION) have emerged.
Faisal A. Al‐Harbi, Mohanad A. Alkuwaiti, Yazeed B. Alaql, Ahmed K. Alsaif, Ahmed A. Alessa, Meshari Ayed Alharbi, Mohammed Alfalah, Saud A. Alnaaim, Sajjad M. AlHaddad, Ahmed Y. Azzam   +9 more
wiley   +1 more source

Dermatological Manifestations of Glucagon‐Like Peptide‐1 Receptor Agonists

JEADV Clinical Practice
Background Glucagon‐like peptide‐1 receptor agonists (GLP‑1 RAs) play a pivotal role in treating type 2 diabetes. Despite their widespread use, their dermatological manifestations remain under‐recognized, hence the interest of this systematic review ...
Nour Ghostine, Maya Halabi‐Tawil
doaj   +1 more source

GLP-1-based combination strategies for weight loss: Multi-target agents and combination therapies

Pharmacological Research
The emergence of glucagon-like peptide-1 receptor agonists (GLP-1RAs) represents a major breakthrough in the pharmacotherapy of obesity. However, their single-target mechanism has limitations.
Xinyao Wang, Rutao Lin, Qinmei Sun, Xin Xin, Qin Feng   +4 more
doaj   +1 more source

Reframing the role of glucagon‐like peptide 1 receptor agonists in cardiovascular medicine

ESC Heart Failure
ESC Heart Failure, Volume 12, Issue 2, Page 923-926, April 2025.
Riccardo M. Inciardi, Alvin Chandra, Ambarish Pandey, Marco Metra   +3 more
doaj   +2 more sources